Incannex Healthcare Inc.
IXHL
Analytical Summary
On an absolute basis, Incannex Healthcare Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.
6-Year Financial Trajectory
Annualinfo Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.
Bullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Invested CapitalReturn on Invested Capital of -140.4% is weak on an absolute basis (target > 10%)
- FCF / Net IncomeFCF / Net Income of 0.27x is weak on an absolute basis (target > 1x)
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ | FY 2022 Jun 30, 2022 20-F ↗ | FY 2021 Jun 30, 2021 20-F ↗ | FY 2020 Jun 30, 2020 20-F ↗ |
|---|---|---|---|---|---|---|
| Revenue Growth YoY (%) |
616.7%
Excellent
Excellent
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+7608%)
|
— | — | — | — | — |
| EPS Growth YoY (%) |
-17.4%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
65.4%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — | — |
| Net Income Growth YoY (%) |
-154.0%
Weak
↓
Weak
Declining
Year-over-year change in net income |
62.2%
Excellent
↑
Excellent
Improving
Year-over-year change in net income |
-227.5%
Weak
↓
Weak
Declining
Year-over-year change in net income |
-31.0%
Weak
Weak
Year-over-year change in net income |
-142.1%
Weak
Weak
Year-over-year change in net income |
— |
| FCF Growth YoY (%) |
63.6%
Excellent
Excellent
Year-over-year change in free cash flow |
-38.7%
Weak
Weak
Year-over-year change in free cash flow |
— | — | — | — |
| Metric | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ | FY 2022 Jun 30, 2022 20-F ↗ | FY 2021 Jun 30, 2021 20-F ↗ | FY 2020 Jun 30, 2020 20-F ↗ |
|---|---|---|---|---|---|---|
| Effective Tax Rate (%) (%) | — |
-0.2%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — | — | — |
| FCF / Net Income (x) |
0.27x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.87x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.23x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— | — | — |
| Metric | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ | FY 2022 Jun 30, 2022 20-F ↗ | FY 2021 Jun 30, 2021 20-F ↗ | FY 2020 Jun 30, 2020 20-F ↗ |
|---|---|---|---|---|---|---|
| Return on Invested Capital (%) |
-140.4%
Weak
↑
Weak
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-268.3%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-188.4%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — | — |
| Return on Capital (%) (%) |
-116.3%
Weak
↑
Weak
Improving
Operating profit relative to total assets
Optimal:
> 10%
|
-176.2%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-208.8%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — |
| Return on Common Equity (%) (%) | — |
-164.6%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1197%)
|
-234.4%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1663%)
|
— | — | — |
| Metric | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ | FY 2022 Jun 30, 2022 20-F ↗ | FY 2021 Jun 30, 2021 20-F ↗ | FY 2020 Jun 30, 2020 20-F ↗ |
|---|---|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $86.00K | $12.00K | — | — | — | — |
| Depreciation Expense (USD) | $143.00B | $103.00B | $23.00M | — | — | — |
| Net Income, GAAP (USD) | $-46.88M | $-18.46M | $-48.81M | $-14.90M | $-11.37M | $-4.70M |
| Operating Cash Flow (USD) | $-12.51M | $-15.85M | $-10.75M | — | — | — |
Secondary lens
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Unavailable
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Benchmarks unavailable
Verdicts use absolute quality thresholds, not peer comparison — only 0 comparable companies are currently available for ranking.
Use Statement Evidence firstCompare IXHL with peers
Stack IXHL against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 6 years · 17 quarters